Patents Examined by Leah H Schlientz
  • Patent number: 11364312
    Abstract: A platinum sulfide protein nanoparticle having near-infrared photothermal effect and multi-modal imaging function, a preparation method therefor and an application thereof. The platinum sulfide nanoparticle having near-infrared photothermal effect and multi-modal imaging function is prepared in aqueous phase by means of formulation screening and process limitation. The nanoparticle has an ultra-small particle size and good stability as well as tumor targeting and photothermal effects and integrates functions of near-infrared imaging, CT imaging, and thermal imaging, so as to achieve high sensitivity, high resolution, and precise positioning of tumors, and to produce high-efficiency photothermal effects under the excitation of near-infrared light to kill tumor cells by thermal ablation, thereby achieving the purpose of efficient, safe, visual, and accurate treatment of tumors. The nanoparticle has the potential for further development and clinical application.
    Type: Grant
    Filed: February 6, 2021
    Date of Patent: June 21, 2022
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Hong Yang, Huabing Chen, Xue Wang, Hengte Ke, Ming Li, Tao Xu, Miya Zhang
  • Patent number: 11346798
    Abstract: The present invention relates to a diagnostic device and methods of using the same for diagnostic assays for monitoring the presence of biological samples wherein the device allows for the determination of at least two assay components on one sensor. More specifically, the invention relates to a multi-marker electrochemical impedance spectroscopy sensor comprising a plurality of molecular recognition elements wherein the sensor comprises multiple different molecular recognition element types that are tuned in a manner that alters the frequency of the molecular recognition element type such that it is at a detectably different frequency to the frequency of other molecular recognition element types on the same sensor.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: May 31, 2022
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Jeffrey LaBelle, Ugur Demirok
  • Patent number: 11344637
    Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: May 31, 2022
    Assignee: CHDI FOUNDATION, INC.
    Inventors: Celia Dominguez, John Wityak, Jonathan Bard, Christopher John Brown, Michael Edward Prime, Peter David Johnson, Thomas Martin Krulle, Daniel Clark-Frew, Duane Higgins, Matthew Robert Mills, Richard Waldron Marston, Samuel Coe, Samantha Brown, Sarah Hayes
  • Patent number: 11330999
    Abstract: The present technology provides 13C- and 15N-labeled probes for imaging one or more mammalian cells using magnetic resonance. Thus, 13C- and 15N-labeled arginine (compound of formula I), xanthine (compounds of formula II and formula III), urea (compounds of formula IV), and glutamine (compounds of formula V), stereoisomers, tautomers, and pharmaceutically acceptable salts thereof are provided. Further methods of making the labelled probes and methods of using the probes to detect arginase, xanthine oxidase, and glutaminase metabolites and activity are provided.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: May 17, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Andrew Cho, Roozbeh Eskandari, Valentina Di Gialleonardo, Kayvan R. Keshari
  • Patent number: 11324841
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly an MRI contrast agent derived from nanoparticle that is porous first metal-doped second metal oxide nanoparticle with a central cavity, and a method for producing the same. The MEI contrast agent made in accordance with the present invention can be used not only as a drug-delivery agent for therapy but also as an MRI contrast agent for diagnosis.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: May 10, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Kwang Yeol Lee, Min Sik Kim, Taek Hoon Kim, Ngoc Phan Vu
  • Patent number: 11305013
    Abstract: The invention relates to an ultrasound contrast agent (UCA) comprising an outer shell and a gas core. The gas core is filled with oxygen, and the outer shell comprises a first surfactant and a second surfactant. The invention also relates to a method of making an oxygen-filled UCA and delivering oxygen to a local area of a subject's body. The method comprises injecting a composition comprising an oxygen-filled UCA of the invention into the subject's body; directing ultrasound radiation to the local area in an intensity sufficient to rupture the UCA.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: April 19, 2022
    Assignees: Drexel University, Thomas Jefferson University
    Inventors: John Robert Eisenbrey, Margaret Alison Wheatley, Patrick O'Kane, Lorenzo Albala, Flemming Forsberg
  • Patent number: 11298324
    Abstract: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: April 12, 2022
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Roger A Rinker, Nicholas J. Casale, James H. Comly, Brenda Pollock, Johan Geerke, Martin Costello, Dennis Wieand, Kishor Parekh
  • Patent number: 11291736
    Abstract: The pH-responsive ultrasensitive fluorescent nanoprobe is composed of pH-responsive matrix materials and fluorescent organic small molecule dyes. The pH-responsive matrix materials are calcium phosphate, calcium hydroxyphosphate, fluorapatite, calcium carbonate or ZIF series; the fluorescent organic small molecule dyes are positively charged dyes or negatively charged dyes. The preparation method includes: coating a positively charged dye with a negatively charged matrix material; coating a negatively charged dye with a negatively charged matrix material; and coating a negatively charged dye with a positively charged matrix material.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: April 5, 2022
    Assignee: XIDIAN UNIVERSITY
    Inventors: Zhongliang Wang, Yongdong Wang, Ruili Zhang, Qian Jia, Chaoqiang Qiao, Jie Tian
  • Patent number: 11285224
    Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: March 29, 2022
    Assignee: MediBeacon Inc.
    Inventors: Richard B. Dorshow, Steven J. Hanley, Phillip I. Tarr
  • Patent number: 11285223
    Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: March 29, 2022
    Assignee: MediBeacon Inc.
    Inventors: Richard B. Dorshow, Steven J. Hanley, Phillip I. Tarr
  • Patent number: 11224666
    Abstract: A functional gadolinium contrast agent comprising a gadolinium cation and a ligand secured to the gadolinium cation is disclosed, the ligand comprising a reactive group capable of bonding to a capture substrate. A method of removing gadolinium contrast agents from a patient is disclosed, the method comprising providing a gadolinium contrast agent containing a reactive group; providing a capture substrate for insertion into a patient's bloodstream; administering the gadolinium contrast agent to the patient; conducting a magnetic resonance imaging procedure; and sequestering the gadolinium contrast agent on the capture substrate. A system for removing gadolinium contrast agents is also disclosed.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: January 18, 2022
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Joseph Thomas Delaney, Jr., Douglas Dean Pagoria, Douglas Pennington, Paul Sorajja
  • Patent number: 11219698
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly a metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent that can be used not only as a T1 MRI contrast agent but also as a T2 MRI contrast agent, and a method for producing the same. The metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent can provide more accurate and detailed information associated with disease than single MRI contrast agent by the beneficial contrast effects in both T1 imaging with high tissue resolution and T2 imaging with high feasibility on detection of a lesion.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: January 11, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Kwang Yeol Lee, Min Sik Kim, Taek Hoon Kim, Ngoc Phan Vu
  • Patent number: 11219689
    Abstract: Boron Enriched Linker (“BEL”) compositions and methods of making BELs are disclosed herein. Consequently, the BELs can be conjugated to antibodies or antibody fragments to create Antibody Boron Conjugates (“ABCs”) to provide a method of treating cancer, immunological disorders and other disease by utilizing a Neutron Capture Therapy modality.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: January 11, 2022
    Assignee: TAE Life Sciences, LLC
    Inventors: Michael Y. Torgov, Tioga J. Martin
  • Patent number: 11213596
    Abstract: An imaging contrast composition comprising an iodinated contrast agent and a ligand secured to the iodinated contrast agent is disclosed, the ligand comprising a reactive group capable of bonding to a capture substrate. A method of removing iodinated radiocontrast agents from a patient is disclosed, the method comprising providing an iodinated radiocontrast agent containing a reactive group; providing a capture substrate for insertion into a patient's bloodstream; administering the iodinated radiocontrast agent to the patient; conducting procedure CT scan or procedure using fluoroscopy; and sequestering the iodinated radiocontrast agent on the capture substrate.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: January 4, 2022
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Joseph Thomas Delaney, Jr., Douglas Dean Pagoria, Richard Lee Tadsen, Andrew J. Ro, Joel T. Eggert, Douglas Pennington, Paul Sorajja, Sarah Melissa Gruba, Tatyana Dyndikova
  • Patent number: 11185598
    Abstract: The invention relates to a process for the preparation of a diagnostic X-ray composition. The composition comprises a non-ionic X-ray contrast agent in a pharmaceutically acceptable carrier. More particularly, the invention relates to a process for secondary production of X-ray compositions comprising X-ray contrast agents with a high dissolution temperature. When using the process of the invention, precipitation is avoided and degradation of the contrast agent is reduced. The process of the invention includes heat treatment of iodinated X-ray contrast agents at low pH.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: November 30, 2021
    Assignee: GE HEALTHCARE AS
    Inventors: Christian Glogard, Dirk-Jan in't Veld
  • Patent number: 11179369
    Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: November 23, 2021
    Assignee: Wyeth LLC
    Inventors: Eric Joel Benjamin, Wendy Ann Dulin, Yanning Lin, Kai Zhuang
  • Patent number: 11156684
    Abstract: Provided are methods for nuclear spin polarization enhancement via signal amplification by reversible exchange at very low magnetic fields.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: October 26, 2021
    Assignees: Duke University, Vanderbilt University, Board of Trustees of Southern Illinois University
    Inventors: Warren S. Warren, Thomas Theis, Eduard Y. Chekmenev, Milton L. Truong, Aaron M. Coffey, Boyd Goodson, Fan Shi, Roman V. Shchepin
  • Patent number: 11147889
    Abstract: Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L1 and L2 are each independently a covalent bond or a divalent linking group, R is a detectable label or therapeutic drug and B is an albumin binding moiety. Also provided are compositions including a compound of Formula (I) together with a pharmaceutically acceptable carrier, and methods for imaging prostate cancer cells using a compound of Formula (I).
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: October 19, 2021
    Assignee: Cancer Targeted Technology LLC
    Inventors: Clifford Berkman, Cindy Choy
  • Patent number: 11129902
    Abstract: The teachings provide methods of delivering active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Delivery systems and methods of making and using the delivery systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: September 28, 2021
    Inventor: Mamoun M Alhamadsheh
  • Patent number: 11116854
    Abstract: A liposomal composition (“ADx-001”) is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: September 14, 2021
    Assignee: Texas Children's Hospital
    Inventors: Eric A. Tanifum, Ketankumar B. Ghaghada, Ananth V. Annapragada